focus -WSS

focus

author：hotspot 2025-09-29 13:46:17 - browse：8

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： With trial win, GSK could get blood cancer drug back on market

WSS

ASCO: Palliative care found as helpful given virtually as in person

New England Journal of Medicine addresses racist history, slavery

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

New menopause drug shows promise in relief for hot flashes

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Wikipedia

focus

leisure time

Heart attack and stroke risk calculators need revising

Ionis drug prevents swelling attacks due to hereditary angioedema

George Santos makes 1st court appearance after pleading not guilty to 13 counts

BMI, flaws aside, is found to be useful estimate of body fat in youth

Medical leaders decry Supreme Court decision on affirmative action

Risky weight loss products often used by teens globally, per study

How one medical school became remarkably diverse

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

23andMe had bad news about my health. I wish a person had delivered it

With trial win, GSK could get blood cancer drug back on market

explore

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO: Palliative care found as helpful given virtually as in person

As JPM 2024 winds down, some health tech firms project optimism

How to increase colonoscopy rates? Looks like an AI can help

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

New Medicare drug pricing powers could soon be upended in court

knowledge

hotspot

focus

hotspot